BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//MedNet - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://mednetus.net
X-WR-CALDESC:Events for MedNet
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230301T080000
DTEND;TZID=America/New_York:20240301T170000
DTSTAMP:20260424T085432
CREATED:20250620T075226Z
LAST-MODIFIED:20250620T075226Z
UID:10000019-1677657600-1709312400@mednetus.net
SUMMARY:Glaucoma: Sustained-release Drug Delivery System\, Topical Agents\, and Emerging 3D Visualization Technologies
DESCRIPTION:CME | CNE 1.00 Credit \n\n\n\nWebcast \nTime to Complete: 1 hour \nReleased: March 1\, 2023 \nExpires: March 1\, 2024 \nMaximum Credits:\n1.00 / AMA PRA Category 1 CreditTM\n1.00 / ANCC Contact Hour \nProgram Description \nGlaucoma is a heterogeneous group of diseases that has become a significant cause of irreversible blindness worldwide. A glaucoma group of optic neuropathies is characterized by progressive degeneration of retinal ganglion cells. These are central nervous system neurons with cell bodies in the inner retina and axons in the optic nerve. Degeneration of these nerves results in cupping\, a characteristic optic disc appearance\, and visual loss. The biological basis of glaucoma is poorly understood\, and the factors contributing to its progression have not been fully characterized. \nIntended Audience \nThis webcast is designed to meet the educational needs of ophthalmologists\, optometrists\, retina specialists\, advanced practice providers\, and nurses caring for a patient with glaucoma. \nCommercial Supporter \nThis activity is supported by an educational grant from Alcon Vision\, LLC. \n\nEducational Objectives \nUpon completion of the educational activity\, participants should be able to: \n\nSummarize the pathophysiology of glaucoma development\nAssess clinical trial data on new sustained-release drug delivery systems and topical agents in the management of glaucoma\nAppraise the utility of 3D visualization in glaucoma surgery\n\nAccredited Providers \nThis activity is provided by Amedco\, a CME/CE company\, and MedNet. \n  \nJoint Accreditation Statement \n \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. \nPhysicians (ACCME) Credit Designation \nDesignation Statement \nAmedco LLC designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. \nNurses (ANCC) Credit Designation \nDesignation Statement \nAmedco LLC designates this activity for a maximum of 1.00 ANCC contact hour. \nAdditional Credit Information \nNote to Physician Assistants\nPAs may claim a maximum of 1.00 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME or a recognized state medical society \nNote to Nurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allows reciprocity for AANPCP continuing education credit for a maximum of 1.00 hour. \nConflicts of Interest Policy \nIt is the policy of the Amedco to ensure activity content is balanced\, independent\, objective and based on scientific best-evidence. All persons in a position to control content (i.e.\, course director\, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation. \nEvery person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose. \nPlanners’ and Managers’ Disclosures \nThe planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast: \nKamatham A. Naidu\, PhD (MedNet) has no relevant financial relationships.\nBrian Waggoner (MedNet) has no relevant financial relationships to disclose.\nSheryl Morgan (Amedco) has no relevant financial relationships to disclose. \nDisclosure of Unlabeled Use \nIt is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label\, unlabeled\, experimental\, and/or investigational (not FDA approved) and of any limitations on the information that is presented\, such as data that are preliminary or that represent ongoing research\, interim analyses\, and/or unsupported opinion. \nEach speaker reported he/she will notify the audience if/when discussion includes off-label\, unlabeled\, experimental\, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation. \nDisclaimer \nThe information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. \nNon-Endorsement of Products \nAmedco do not imply either real or implied endorsement of any product\, service\, or company referred to in this educational activity. \nFaculty \nRobert Chang\, MD\nAssociate Professor of Ophthalmology\nStanford University\nPalo Alto\, CA \nDr. Chang discloses the following:\nResearch support: Alcon and Genentech\nConsultant: Alcon\, Genentech\, 1800 Contacts\, Verana Heath\, Sight Sciences\, Ocular Therapeutix\, Apple\, and Belken\nAdvisor: Smartlens and XP Health\nSPV: Iantrek \nFelipe A Medeiros\, MD\, PhD\nJoseph AC Wadsworth Distinguished Professor of Ophthalmology\nProfessor of Electrical and Computer Engineering\, and Biostatistics\nDuke University\, Durham\, NC \nDr. Medeiros discloses the following:\nResearch support: National Eye Institute R01 EY029885\, R43 EY027651\, Carl-Zeiss Meditec\, Inc.\, Heidelberg Engineering\, GmBH\, Reichert\, and Google\, Inc.\nConsultant: Allergan\, Inc.\, Novartis\, Inc.\, Reichert; \, Carl-Zeiss\, Inc.\, Galimedix\, Biogen\, Stealth Therapeutics\, Annexon \nInstructions \nThere are no fees for participating and receiving CME/CE credit for this webcast. During the period from March 1\, 2023\, through March 1\, 2024\, participants must read all the material and study the educational webcast. \nThis webcast includes text\, graphics\, and may include multimedia features. \nIn order to receive CME/CE credits\, participants must complete the pre-assessment questions\, post-assessment\, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript\, which you can access at any time. \nIf you have any questions relating to the accreditation of this activity\, please contact the CME/CE Provider at certificate@amedcoemail.com. \nPrivacy Policy \nAmedco observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities that are relevant to their interests and/or the activities they support. \nmyCME privacy policy
URL:https://mednetus.net/event/glaucoma-sustained-release-drug-delivery-system-topical-agents-and-emerging-3d-visualization-technologies/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/s3oowug5n25y-800x450-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240210
DTEND;VALUE=DATE:20250211
DTSTAMP:20260424T085432
CREATED:20250620T074507Z
LAST-MODIFIED:20250620T074507Z
UID:10000018-1707523200-1739231999@mednetus.net
SUMMARY:New Prospects in Blood-based Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease
DESCRIPTION:February 10\, 2024 \n\n\nTake Me to the Event Registration\n\n\nEVENT Summary \nDates \nSaturday\, February 10\, 2024\, 11:00 AM ET\, 10:00 AM CT\, and 9:00 AM MT \nLocation \nVirtual \nTarget Audience \nNeurologists\, nurse practitioners\, and physician assistants involved in Alzheimer’s disease patient care. \nFormat \nZoom Webinar \nCredits \n1.50 / AMA PRA Category 1 Credit(s)TM \nCost \nFree \nProgram Description \nClick to Go to the Event Registration \nThis webinar provides an update on the blood-based markers (BBMs) improve randomized clinical trials (RCTs) design and conduct of Alzheimer’s disease. It remains to be determined if the data available on BBMs are strong enough to replace CSF and PET biomarkers as entry criteria and monitoring tools in RCTs. Strategies to optimize and guide disease-modifying anti-amyloid antibody (AAA) therapies based on BBMs in managing patients with early-stage AD. \nAgenda \n\nDiscuss the blood-based biomarkers in diagnosing early-stage Alzheimer’s disease (AD) and its utility in the prevention – Jeremy Pruzin\, MD\nDiscuss clinical trial data on safety-efficacy profiles of approved and investigational disease-modifying anti-amyloid antibody therapies in managing early AD – Marwan Sabbagh\, MD\n\nIntended Audience \nNeurologists\, nurse practitioners\, and physician assistants involved in Alzheimer’s disease patient care. \nCommercial Supporter \nSupported by an educational grant from Eisai\, Inc. \nLearning Objectives \n\nSummarize the pathophysiology and the clinical presentation of Alzheimer’s disease (AD).\nAssess the blood-based biomarkers in diagnosing early-stage AD and its utility in the prevention.\nIdentify strategies to optimize disease-modifying anti-amyloid antibody (AAA) therapies in managing patients with early-stage AD.\n\nAccredited Providers \nAmedco and MedNet have collaborated to design and execute this activity. \n       \nPhysicians (ACCME) Credit \n\nJoint Accreditation Statement \nIn support of improving patient care\, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME)\, the Accreditation Council for Pharmacy Education (ACPE)\, and the American Nurses Credentialing Center (ANCC)\, to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163. \n\n\nDesignation Statement \nAmedco LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\nAdditional Credit Information \nPhysician Assistants\nPAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. \nNurse Practitioners\nThe American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.5 hours. \nDisclosures of Relationships with Ineligible Companies Policy \nIn accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education\, all faculty\, planning committee members\, and other individuals\, who are in a position to control content\, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance\, scientific objectivity\, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated. \nOff-Label Disclosure Statement \nFaculty members are required to inform the audience when they are discussing off-label\, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity. \nFaculty \n \nJeremy Pruzin\, MD\nBehavioral Neurologist\nBanner Alzheimer’s Institute\nTucson\, AZ \n \nMarwan Sabbagh\, MD\nProfessor of Neurology\nBarrow Neurological Institute\nPhoenix\, AZ \nInstructions/Technical Requirements \n\nA desktop or laptop computer or a mobile device with a stable internet connection and audio capability is required to attend. Joining via mobile or tablet is possible but not recommended.\nTimes in the portal adjust to your computer; however\, some browsers have a separate time zone adjustment.\nFor the best viewing experience\, we recommend the following browsers: Chrome\, Firefox\, and Safari. For attendees viewing on Internet Explorer 11\, you may experience lags in streaming. To maximize your attendee hub experience\, we recommend you not sign in through your company assigned VPN.\nEnsure that your computer’s sound is enabled for your browser and allow permissions to the On24 Attendee Hub platform if necessary.\n\nCost \nComplimentary \nContact \nBrian Waggoner\nProgram Manager\nMedNet\nbrianw@mmhus.net
URL:https://mednetus.net/event/new-prospects-in-blood-based-biomarkers-and-disease-modifying-anti-amyloid-antibody-therapies-for-early-stage-alzheimers-disease-2/
CATEGORIES:Live Program
ATTACH;FMTTYPE=image/jpeg:https://mednetus.net/wp-content/uploads/2025/06/lguvvkalmx2k-Banner800x450.jpg
END:VEVENT
END:VCALENDAR